|

Parkinson's Disease Clinical Trials in Connecticut

19 recruiting studies across 6 cities

All Trials in Connecticut

Phase
Trial Phase Location
Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder—Branford
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's DiseasePhase 2/3Farmington
Daily Amino Acid Supplementation for People With Parkinson's DiseaseN/AFarmington
Parkinson's Foundation PD GENEration Genetic Registry—Farmington
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's DiseasePhase 1New Haven
A Comparative Performance Study Between High and Standard Resolution Positron Emission Tomography Camera Using [18F] AV-133 in Prodromal Parkinson's DiseasePhase 2New Haven
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseasePhase 3New Haven
A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications—New Haven
Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)Phase 2New Haven
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's DiseasePhase 2New Haven
Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy VolunteersEarly 1New Haven
Imaging Depression in Parkinson's DiseasePhase 2New Haven
MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)Phase 1New Haven
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort—New Haven
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503Early 1New Haven
The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseasePhase 2New Haven
This Protocol is a Sub-study Under the PPMI Program. It is a Longitudinal, Single-center Study to Assess the Performance of [18F]AV-133 Imaging Using High and Standard Resolution PET in Individuals Enrolled With Parkinson's Disease (PD) for up to 12 Months.Phase 2New Haven
A Study of Buntanetap in Participants With PDPhase 2/3Stamford
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic TherapyPhase 2Stamford

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.